See today's BioWorld Science
To read the full story, subscribe or sign in.
Immuno-oncology

Ono and Ligachem sign licensing agreement for ADC LCB-97 for solid tumors

Oct. 10, 2024
Ono Pharmaceutical Co. Ltd. has entered into a license agreement with Ligachem Biosciences Inc. for LCB-97, a preclinical stage antibody-drug conjugate (ADC) for solid tumors.
BioWorld Science Deals and M&A Collaboration License Cancer Antibody-drug conjugate Immuno-oncology